A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)

This trial is a registrational Phase II/III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in combination with osimertinib in resectable EGFR-mutant non-small cell lung cancer.

Trial Details

NCT ID

NCT07642024

Phase

PHASE2 / PHASE3

Sponsor

Sichuan Baili Pharmaceutical Co., Ltd.

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

BL-B01D1
Osimertinib
Carboplatin
Pemetrexed
Cisplatin

Locations (sample)

Shanghai, Shanghai Municipality, China|31.22222,121.45806
Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

Voluntarily sign informed consent and agree to comply with the protocol requirements;
Aged ≥18 years and ≤75 years, regardless of gender;
Expected survival time ≥3 months;
Patients with non-small cell lung cancer;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →